Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 37

Sort by

Sort Order Select

Journal Articles

What to do with minimal residual disease testing in myeloma

Elisabet E. Manasanch

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 137–141.

https://doi.org/10.1182/hematology.2019000080

Published: 2019

Journal Articles

Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?

Surbhi Sidana, Elisabet Manasanch

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 142–147.

https://doi.org/10.1182/hematology.2019000075

Published: 2019

Journal Articles

Myeloma: next generation immunotherapy

Adam D. Cohen

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 266–272.

https://doi.org/10.1182/hematology.2019000068

Published: 2019

Journal Articles

Minimal residual disease and stem cell transplantation outcomes

Jacqueline Cloos, Gert J. Ossenkoppele, Richard Dillon

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 617–625.

https://doi.org/10.1182/hematology.2019000006

Published: 2019

Journal Articles

Relapsed disease and aspects of undetectable MRD and treatment discontinuation

Barbara Eichhorst, Moritz Fürstenau, Michael Hallek

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 482–489.

https://doi.org/10.1182/hematology.2019000070

Published: 2019

Journal Articles

Navigating the nexus of MRD and novel agents in ALL

Anjali S. Advani, Edward A. Copelan

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 9–16.

https://doi.org/10.1182/hematology.2019000008

Published: 2019

Journal Articles

Is molecular remission the goal of multiple myeloma therapy?

Faith E. Davies

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 205–211.

https://doi.org/10.1182/asheducation-2017.1.205

Published: 2017

Journal Articles

Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation

Monika Brüggemann, Michaela Kotrova

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 13–21.

https://doi.org/10.1182/asheducation-2017.1.13

Published: 2017

Journal Articles

Current management of Philadelphia chromosome positive ALL and the role of stem cell transplantation

Farhad Ravandi

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 22–27.

https://doi.org/10.1182/asheducation-2017.1.22

Published: 2017

Journal Articles

Progress in adult ALL: incorporation of new agents to frontline treatment

Jessica Leonard, Wendy Stock

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 28–36.

https://doi.org/10.1182/asheducation-2017.1.28

Published: 2017

Journal Articles

MRD in AML: does it already guide therapy decision-making?

Gert Ossenkoppele, Gerrit Jan Schuurhuis

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 356–365.

https://doi.org/10.1182/asheducation-2016.1.356

Published: 2016

Journal Articles

Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment

Eva Hoster, Christiane Pott

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 437–445.

https://doi.org/10.1182/asheducation-2016.1.437

Published: 2016

Journal Articles

Management of adult Ph-positive acute lymphoblastic leukemia

Sabina Chiaretti, Robin Foà

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 406–413.

https://doi.org/10.1182/asheducation-2015.1.406

Published: 2015

Journal Articles

Detection and management of minimal residual disease in acute lymphoblastic leukemia

Martin Schrappe

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 244–249.

https://doi.org/10.1182/asheducation-2014.1.244

Published: 2014

Journal Articles

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?

David Grimwade, Sylvie D. Freeman

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 222–233.

https://doi.org/10.1182/asheducation.V2014.1.222.3884425

Published: 2014

Journal Articles

Transplantation for mantle cell lymphoma: is it the right thing to do?

Michael E. Williams

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 568–574.

https://doi.org/10.1182/asheducation-2013.1.568

Published: 2013

Journal Articles

Novel clinical trials for pediatric leukemias: lessons learned from genomic analyses

Andrea Biondi, Giovanni Cazzaniga

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 612–619.

https://doi.org/10.1182/asheducation-2013.1.612

Published: 2013

Journal Articles

Minimal residual disease in acute myeloid leukemia: coming of age

Elisabeth Paietta

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 35–42.

https://doi.org/10.1182/asheducation.V2012.1.35.3797926

Published: 2012

Journal Articles

Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patient

Martin Schrappe

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 137–142.

https://doi.org/10.1182/asheducation.V2012.1.137.3798216

Published: 2012

Journal Articles

A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia?

Paolo Ghia

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 97–104.

https://doi.org/10.1182/asheducation.V2012.1.97.3798195

Published: 2012

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

What to do with minimal residual disease testing in myeloma

Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?

Myeloma: next generation immunotherapy

Minimal residual disease and stem cell transplantation outcomes

Relapsed disease and aspects of undetectable MRD and treatment discontinuation

Navigating the nexus of MRD and novel agents in ALL

Is molecular remission the goal of multiple myeloma therapy?

Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation

Current management of Philadelphia chromosome positive ALL and the role of stem cell transplantation

Progress in adult ALL: incorporation of new agents to frontline treatment

MRD in AML: does it already guide therapy decision-making?

Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment

Management of adult Ph-positive acute lymphoblastic leukemia

Detection and management of minimal residual disease in acute lymphoblastic leukemia

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?

Transplantation for mantle cell lymphoma: is it the right thing to do?

Novel clinical trials for pediatric leukemias: lessons learned from genomic analyses

Minimal residual disease in acute myeloid leukemia: coming of age

Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patient

A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia?

ASH Publications

American Society of Hematology

Update search

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only